CCND1 and familial pancreatic carcinoma: The combination of MJ (0.1 nM) and BCNU (carmustine) therapy (1, 10 and 25 μg/mL—PaCa-2 cell; 2.5 and 5 μg/mL—BCL1 cell) had an adverse effect on pancreatic cancer cells (PaCa-2; BCL1) causing their apoptosis, which was not observed with BCNU alone.